ライフサイエンスコーパス: cervical intraepithelial neoplasia

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 d anogenital intraepithelial neoplasias (eg, cervical intraepithelial neoplasia).

2 of 345 women who were at risk of developing cervical intraepithelial neoplasia.

3 of both HPV-16 infection and HPV-16-related cervical intraepithelial neoplasia.

4 ssociated virus influenced the production of cervical intraepithelial neoplasia.

5 tion of women before and after treatment for cervical intraepithelial neoplasia.

6 h abnormal Papanicolou smears, indicative of cervical intraepithelial neoplasia.

7 hich cause 70% of cervical cancer and 50% of cervical intraepithelial neoplasia 2/3 and adenocarcinom

8 Development of cervical intraepithelial neoplasia 2/3 was rare in women

9 s limited benefit to reduce the incidence of cervical intraepithelial neoplasia 3 and no benefit to r

10 mary-screening algorithm found more disease (cervical intraepithelial neoplasia 3 or worse [CIN3+]) a

11 35; 95% CI, 1.67 to 3.31); grade 2 or higher cervical intraepithelial neoplasia, 6.9% vs. 3.4% (hazar

12 Biopsy tissue was evaluated for cervical intraepithelial neoplasia and analyzed for HPV-

13 ncer-derived cell lines and human tissues of cervical intraepithelial neoplasia and cervical cancer.

14 stion: Does local conservative treatment for cervical intraepithelial neoplasia and early invasive ce

15 ansmitted pathogen capable of giving rise to cervical intraepithelial neoplasia and invasive carcinom

16 helium is low but increases significantly in cervical intraepithelial neoplasia and invasive squamous

17 Conservative methods to treat cervical intraepithelial neoplasia and microinvasive cer

18 oteins resulted in development of high-grade cervical intraepithelial neoplasia, but not frank cervic

19 fidence interval [CI], 5.1% to 28.7%) and of cervical intraepithelial neoplasia (CIN) 1-3 or adenocar

20 e reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocar

21 previously used this probe set to show that cervical intraepithelial neoplasia (CIN) 2 and CIN3 lesi

22 papillomavirus (HPV) during the follow-up of cervical intraepithelial neoplasia (CIN) 2/3 after biops

23 cterize the local immune microenvironment in cervical intraepithelial neoplasia (CIN) 2/3 and determi

24 The authors assessed risk factors for cervical intraepithelial neoplasia (CIN) among southwest

25 ct data about test performance for detecting cervical intraepithelial neoplasia (CIN) and cancer and

26 e frequently diagnosed with higher grades of cervical intraepithelial neoplasia (CIN) and cancer, as

27 n strongly implicated in the pathogenesis of cervical intraepithelial neoplasia (CIN) and cervical ca

28 rogression of HPV-related disease, including cervical intraepithelial neoplasia (CIN) and invasive ce

29 nown about the long-term yield of high-grade cervical intraepithelial neoplasia (CIN) and the influen

30 Conservative outpatient therapy for cervical intraepithelial neoplasia (CIN) by ablative or

31 Over 60,000 women are treated for cervical intraepithelial neoplasia (CIN) each year in En

32 gated 12 high-grade and 4 low-grade cases of cervical intraepithelial neoplasia (CIN) for LOH after l

33 ions occur in CC progression, we analysed 33 cervical intraepithelial neoplasia (CIN) for LOH.

34 rd deviation]) with histologically confirmed cervical intraepithelial neoplasia (CIN) found on smear

35 ogy, 137 cases with histologically confirmed cervical intraepithelial neoplasia (CIN) grade 1 (CIN1),

36 we determined the cumulative 2-year risks of cervical intraepithelial neoplasia (CIN) grade 2 or more

37 ection, the 36-month cumulative incidence of cervical intraepithelial neoplasia (CIN) grade 2 was 20.

38 Cases were defined as women classified with cervical intraepithelial neoplasia (CIN) grade 2+ (CIN2+

39 sk of relapse after treatment for high-grade cervical intraepithelial neoplasia (CIN) has important c

40 reening history and histologically confirmed cervical intraepithelial neoplasia (CIN) in 2.5 years af

41 Increased risk for cervical intraepithelial neoplasia (CIN) in human immuno

42 sion along the entire neoplastic spectrum of cervical intraepithelial neoplasia (CIN) in the process

43 for oncogenic human papillomaviruses (HPVs), cervical intraepithelial neoplasia (CIN) is common, and

44 vaccine efficacy of 100% (42.4-100) against cervical intraepithelial neoplasia (CIN) lesions associa

45 ce; squamous intraepithelial lesion (SIL) or cervical intraepithelial neoplasia (CIN) prevalence, inc

46 To determine the population-based cervical intraepithelial neoplasia (CIN) trends when adj

47 cervical specimens, including 38 normal, 52 cervical intraepithelial neoplasia (CIN), and 68 cervica

48 ectrum of cervical disease: cervical cancer, cervical intraepithelial neoplasia (CIN), and HPV infect

49 d 5 (56%) of 9 HPV-16-positive women without cervical intraepithelial neoplasia (CIN), respectively.

50 Four PV types were associated with cervical intraepithelial neoplasia (CIN), which resemble

51 ervical cancer and its precursor, high-grade cervical intraepithelial neoplasia (CIN).

52 ected at the time of diagnosis of high-grade cervical intraepithelial neoplasia (CIN).

53 ation between human papillomavirus (HPV) and cervical intraepithelial neoplasia (CIN).

54 ytology for the identification of high-grade cervical intraepithelial neoplasia (CIN).

55 women were followed semiannually for HPV and cervical intraepithelial neoplasia (CIN).

56 us (HPV) types in a broader group that cause cervical intraepithelial neoplasia (CIN).

57 han cytology for the detection of high-grade cervical intraepithelial neoplasia (CIN).

58 apillomaviruses (HPV) results in precancers [cervical intraepithelial neoplasia (CIN)] and cancers ne

59 sue specimens with normal cervix (20 cases), cervical intraepithelial neoplasia (CIN; CIN 1, 27 cases

60 ush specimens from 149 women with high-grade cervical intraepithelial neoplasias (CIN II-CIN III), 17

61 from preinvasive dysplastic lesions, termed cervical intraepithelial neoplasias (CIN), grades I-III.

62 revealing intense angiogenesis in high-grade cervical intraepithelial neoplasias (CIN-3) and carcinom

63 gnificantly increased with disease severity (cervical intraepithelial neoplasia [CIN] 3, 17.9% [+/-7.

64 Cs and their accompanying precursor lesions (cervical intraepithelial neoplasia, CIN; n = 40) and nor

65 hosphorylated STAT3 increased from low-grade cervical intraepithelial neoplasia (CIN1) to precancerou

66 mples spanning normalcy, increasingly severe cervical intraepithelial neoplasia (CIN1- CIN3), and cer

67 eck with HC2 for the detection of high-grade cervical intraepithelial neoplasia (CIN2+) in a total of

68 cific than cytology for detecting high-grade cervical intraepithelial neoplasia (CIN2+).

69 on between persistent HPV DNA and high-grade cervical intraepithelial neoplasia (CIN2-3), high-grade

70 the time span of progression from high-grade cervical intraepithelial neoplasia (CIN2/3) to invasive

71 tests for the ability to predict high-grade cervical intraepithelial neoplasias (CIN2 or worse) in c

72 lative incidence rates (CIRs) of >/= grade 3 cervical intraepithelial neoplasia (CIN3+) or cancer for

73 In cervical intraepithelial neoplasias from patients who we

74 s (HSILs) diagnosed cytologically; 1198 with cervical intraepithelial neoplasia grade 1 (CIN1), 456 w

75 layers in eight of nine cases of HPV16/18(+) cervical intraepithelial neoplasia grade 1 (CIN1); howev

76 cacy against 6-month persistent infection or cervical intraepithelial neoplasia grade 1 or greater (C

77 associated with older age and a diagnosis of cervical intraepithelial neoplasia grade 1 or greater.

78 cacy against 6-month persistent infection or cervical intraepithelial neoplasia grade 1 or higher (CI

79 d for each channel based on the detection of cervical intraepithelial neoplasia grade 2 (CIN2) or gre

80 detection, clinical performance in detecting cervical intraepithelial neoplasia grade 2 (CIN2) or mor

81 histologic diagnosis of controls (less than cervical intraepithelial neoplasia grade 2 [<CIN2]) or c

82 th highest viral load, which varied by type (cervical intraepithelial neoplasia grade 2 [CIN2] for HP

83 history of a high-grade precancerous lesion (cervical intraepithelial neoplasia grade 2 or 3) or cerv

84 re incidence of high-grade cervical disease (cervical intraepithelial neoplasia grade 2 or 3, adenoca

85 riage Study, we selected women with incident cervical intraepithelial neoplasia grade 2 or grade 3 (C

86 Cumulative risks of cervical intraepithelial neoplasia grade 2 or greater (C

87 luated against 6-month persistent infection, cervical intraepithelial neoplasia grade 2 or greater (C

88 ficity of the Xpert HPV for the detection of cervical intraepithelial neoplasia grade 2 or higher (CI

89 thelial neoplasia grade 2 [<CIN2]) or cases (cervical intraepithelial neoplasia grade 2 or higher [CI

90 lasia grades 2/3 and adenocarcinoma in situ (cervical intraepithelial neoplasia grade 2 or higher [CI

91 The sensitivity of Xpert for cervical intraepithelial neoplasia grade 2 or more sever

92 prevention have used the disease endpoint of cervical intraepithelial neoplasia grade 2 or worse (CIN

93 nual reading for the detection of underlying cervical intraepithelial neoplasia grade 2 or worse (CIN

94 difference in vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 2 or worse in H

95 and PATRICIA criteria, VE estimates against cervical intraepithelial neoplasia grade 2 or worse, reg

96 of the Onclarity assay for the detection of cervical intraepithelial neoplasia grade 2+ (CIN2+) and

97 Both assays detected >/=91.7% of cervical intraepithelial neoplasia grade 2+ (CIN2+) lesi

98 As a result, we identified 90 women with cervical intraepithelial neoplasia grade 2+ (CIN2+), inc

99 lial neoplastic lesions and invasive cancer (cervical intraepithelial neoplasia grade 2+ [CIN2+]) com

100 We assessed if risk of developing cervical intraepithelial neoplasia grade 2/3 (CIN2/3) or

101 -grade squamous intraepithelial lesions (ie, cervical intraepithelial neoplasia grade 2/3 [CIN 2/3])

102 d biopsies from patients with HPV-associated cervical intraepithelial neoplasia grade 2/3 and murine

103 ments made on normal tissue and that showing cervical intraepithelial neoplasia grade 2/3; the area u

104 d lowest specificity (46%-54%) for consensus cervical intraepithelial neoplasia grade 3 (CIN 3).

105 ion between the HPV DNA load and the risk of cervical intraepithelial neoplasia grade 3 (CIN-3) diffe

106 were most likely to persist and progress to cervical intraepithelial neoplasia grade 3 (CIN3) and ca

107 r this substudy was histologically confirmed cervical intraepithelial neoplasia grade 3 (CIN3) or wor

108 ify women at high risk of cervical cancer or cervical intraepithelial neoplasia grade 3 (CIN3) or wor

109 and premalignancies in women diagnosed with cervical intraepithelial neoplasia grade 3 (CIN3).

110 13 oncogenic HPV types, for the detection of cervical intraepithelial neoplasia grade 3 and cancer (C

111 The baseline specimens from 482 cases of cervical intraepithelial neoplasia grade 3 or cancer (CI

112 er and its immediate precancerous precursor, cervical intraepithelial neoplasia grade 3 or carcinoma

113 Similar results were observed for cervical intraepithelial neoplasia grade 3 or higher (CI

114 The primary endpoint was cervical intraepithelial neoplasia grade 3 or more sever

115 igated the timing of diagnosis of histologic cervical intraepithelial neoplasia grade 3 or worse (CIN

116 he primary outcome was the detection rate of cervical intraepithelial neoplasia grade 3 or worse (CIN

117 ral persistence and/or precancer and cancer [cervical intraepithelial neoplasia grade 3+ (CIN3+)].

118 cimens from women with a diagnosis of CIN3+ (cervical intraepithelial neoplasia grade 3+ or cervical

119 uding 54 women with histologically confirmed cervical-intraepithelial neoplasia grade 2 or worse [>or

120 d with tests for hrHPV and HPV 16/18 to find cervical intraepithelial neoplasia (grade >/=2 [CIN2+] o

121 d with tests for hrHPV and HPV 16/18 to find cervical intraepithelial neoplasia (grade >/=2 [CIN2+] o

122 rmined significance or greater (ASCUS+), and cervical intraepithelial neoplasia grades 1/2 or greater

123 mavirus 31 (HPV31) DNA loads and the risk of cervical intraepithelial neoplasia grades 2 and 3 (CIN2-

124 Cervical cancer and its obligate precursors, cervical intraepithelial neoplasia grades 2 and 3 (CIN2/

125 53.3% (95% CI = 37.9 to 68.3) for diagnosing cervical intraepithelial neoplasia grades 2/3 (CIN2/3) o

126 icut (CT) implemented mandatory reporting of cervical intraepithelial neoplasia grades 2/3 and adenoc

127 f the spinous cells in benign lesions and in cervical intraepithelial neoplasia grades I and II.

128 Methods used to diagnose and treat cervical intraepithelial neoplasia have important potent

129 cip1 antigen-positive cells were sporadic in cervical intraepithelial neoplasia III and rare and foca

130 Twenty per cent of cervical intraepithelial neoplasias-III (CIN-III) progre

131 tudies revealed the presence of condyloma or cervical intraepithelial neoplasia in 16 women (24.6%) a

132 l lesions was decoded from five grade 2 or 3 cervical intraepithelial neoplasia lesion (CIN2/3) sampl

133 Cervical intraepithelial neoplasia lesions of grade two

134 All nine cases of HPV-16-related cervical intraepithelial neoplasia occurred among the pl

135 ative tests, the prevalence of biopsy-proven cervical intraepithelial neoplasia of grade 2 was 0.028

136 currence of residual or recurrent high-grade cervical intraepithelial neoplasia of grade two or worse

137 development toward clinical testing against cervical intraepithelial neoplasia or carcinoma.

138 All the excisional procedures to treat cervical intraepithelial neoplasia present similar pregn

139 There was no link with cervical intraepithelial neoplasia status and detection

140 However, high-grade cervical intraepithelial neoplasia was found more freque

141 Lynch syndrome, clonal hematopoiesis, and cervical intraepithelial neoplasia which also serve as m

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。